epiPANCANCER- a Novel Blood Test for Accurate Early Detection of Cancer from 33 Different Originas Using a BCD-next Generation Method
CELL FREE TUMOR- DERIVED DNA IN PLASMA It is widely established by now that tumor DNA is shed into the
CELL FREE TUMOR- DERIVED DNA IN PLASMA It is widely established by now that tumor DNA is shed into the
HKG Epitherapeutics co-authored the scientific study aimed to identify DNA methylation markers along the continuum of cervical intraepithelial neoplasia (CIN) to cervical cancer.
We support 24 hours a day
You have 30 days to return
100% Secure & Safe
MTL Epitherapeutics
600 – 2000 Avenue McGill College, Montreal, QC, Canada H3A 3H3
+1 (514) 448-2185
For Kit Deliveries and Sample Submissions
(Return Address for Saliva Samples)
Suite 326, 3551 St. Charles Blvd, Kirkland, QC, Canada H9H 3C4
EpiMedTechGlobal (EMTG)
60 Paya Lebar Road,
#08-06 Paya Lebar Square
Singapore 409051
US Epitherapeutics
1829 Reisterstown Rd, Suite: 350 Baltimore, MD 21208
+1 (347) 216 0654
HKG epiTherapeutics
Unit 313-315, 3/F Biotech Centre 2
11 Science Park West Avenue
Hong Kong Science Park
Shatin, N.T., Hong Kong
Founded in 2016 by Prof. Moshe Szyf, a global pioneer in the dynamic and rapidly evolving field of epigenetics, EpiMedTech Global (EMTG) stands as a force driving innovation. Headquartered in Singapore, EMTG operates a research and diagnostic lab at the Hong Kong Science Park, which serves as the epicenter of groundbreaking endeavors. Additionally, our innovation and bioinformatics arm, MTL Epitherapeutics, is based in Montreal, Canada. Our dedicated scientists are committed to advancing epigenetics and early disease detection. At EMTG, it’s not just about detecting diseases; it’s about offering solutions that promote longevity through the hidden stories in our DNA.